TY - JOUR
T1 - The timing of expression of blood coagulation abnormality in patients treated with warfarin and S-1 concomitantly
AU - Yamada, Takaaki
AU - Watanabe, Hiroyuki
AU - Yano, Takahisa
AU - Nonaka, Toshiharu
AU - Takada, Atsushi
AU - Sonoda, Masanobu
AU - Kubota, Toshio
AU - Egashira, Nobuaki
AU - Oishi, Ryozo
PY - 2010/7
Y1 - 2010/7
N2 - Although S-1 is frequently used in cancer chemotherapy, the drug interaction with warfarin, an anticoagulant agent, is not fully paid attention. In the present study, we investigated retrospectively the timing of expression of blood coagulation abnormality in nine patients treated with warfarin and S-1 concomitantly. In five patients, the dose of warfarin was reduced or interrupted after concomitant use of S-1. The International Normalized Ratio (INR) was significantly increased after combination with S-1 compared with the former value. In all patients, the INR was increased in three weeks after combination with S-1. On the other hand, serum creatinine, aspartate aminotransferase, alanine aminotransferase or serum albumin was not different before and after combination with S-1. These results suggest that the careful monitoring of the blood coagulation ability is necessary in all patients receiving warfarin and S-1 concomitantly.
AB - Although S-1 is frequently used in cancer chemotherapy, the drug interaction with warfarin, an anticoagulant agent, is not fully paid attention. In the present study, we investigated retrospectively the timing of expression of blood coagulation abnormality in nine patients treated with warfarin and S-1 concomitantly. In five patients, the dose of warfarin was reduced or interrupted after concomitant use of S-1. The International Normalized Ratio (INR) was significantly increased after combination with S-1 compared with the former value. In all patients, the INR was increased in three weeks after combination with S-1. On the other hand, serum creatinine, aspartate aminotransferase, alanine aminotransferase or serum albumin was not different before and after combination with S-1. These results suggest that the careful monitoring of the blood coagulation ability is necessary in all patients receiving warfarin and S-1 concomitantly.
UR - http://www.scopus.com/inward/record.url?scp=77955945559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955945559&partnerID=8YFLogxK
U2 - 10.1248/yakushi.130.955
DO - 10.1248/yakushi.130.955
M3 - Article
C2 - 20606375
AN - SCOPUS:77955945559
SN - 0031-6903
VL - 130
SP - 955
EP - 960
JO - Yakugaku Zasshi
JF - Yakugaku Zasshi
IS - 7
ER -
